Quark Aims to Pursue IPO in ’08 as It Builds Image, Develops Novel siRNAs | GenomeWeb
Unfavorable market conditions combined with an unwillingness to cut its proposed share price led to Quark Pharmaceuticals’ decision to scuttle a proposed initial public offering earlier this summer, Quark CEO Danny Zurr told RNAi News this week.
However, the company has not abandoned plans to go public. According to Zurr, Quark is now aiming to float its shares next year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.